Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276600 · ClinicalTrials.gov registry record · Phase 1
Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers
A Phase 1 study, sponsored by HIV Prevention Trials Network.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01276600 is a Phase 1 study that has completed, run by HIV Prevention Trials Network. The registered enrollment target is 32 participants.
The verdict
NCT01276600, a Phase 1 study, has completed, sponsored by HIV Prevention Trials Network.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Describe the dose-proportionality and intra-individual variability of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) at steady-state in healthy human participants taking Truvada® (FTC 200mg/TDF 300 mg) under direct observation.
Interventions
- DRUG Emtricitabine/tenofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01276600
The ClinicalTrials.gov registry entry for NCT01276600 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HIV Prevention Trials Network, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Emtricitabine/tenofovir is the first listed.
NCT01276600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01276600 about?
NCT01276600 is a clinical study titled "Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers". Describe the dose-proportionality and intra-individual variability of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) at steady-state in healthy human participants taking Truvada® (FTC 200mg/TDF 300 mg) under direct observation.
What is the current status of trial NCT01276600?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-01. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01276600?
The interventions under investigation include: Emtricitabine/tenofovir (DRUG).
Who is sponsoring clinical trial NCT01276600?
This trial is sponsored by HIV Prevention Trials Network, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.